Skip to main content
SpringerLink
Log in

Are upgraded DCE-positive PI-RADS 3 lesions truly suspicious for clinically significant prostate cancer?

  • Commentary
  • Published:
European Radiology Aims and scope Submit manuscript

The Original Article was published on 13 April 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Westphalen AC, McCulloch CE, Anaokar JM et al (2020) Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology 296:76–84. https://doi.org/10.1148/radiol.2020190646

    Article  PubMed  Google Scholar 

  2. Mazzone E, Stabile A, Pellegrino F et al (2020) Positive predictive value of prostate imaging reporting and data system version 2 for the detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 4:697–713. https://doi.org/10.1016/j.euo.2020.12.004

    Article  PubMed  Google Scholar 

  3. Mottet N, van den Bergh RC, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79:243–262. https://doi.org/10.1016/j.eururo.2020.09.042

    Article  CAS  PubMed  Google Scholar 

  4. Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777. https://doi.org/10.1056/NEJMoa1801993

    Article  PubMed  PubMed Central  Google Scholar 

  5. Rouvière O, Puech P, Renard-Penna R et al (2019) Use of prostate systematic and targeted biopsy based on multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20(1):100–109. https://doi.org/10.1016/S1470-2045(18)30569-2

  6. Messina E, Pecoraro M, Laschena L et al (2023) Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization? Eur Radiol. https://doi.org/10.1007/s00330-023-09605-0

    Article  PubMed  Google Scholar 

  7. Sigle A, Borkowetz A, von Hardenberg J et al (2023) Prediction of significant prostate cancer in equivocal magnetic resonance imaging lesions: a high-volume international multicenter study. Eur Urol Focus S2405-4569(23)00038-X. https://doi.org/10.1016/j.euf.2023.01.020

  8. Pellegrino F, Tin AL, Martini A et al (2023) Prostate-specific antigen density cutoff of 0.15 ng/ml/cc to propose prostate biopsies to patients with negative magnetic resonance imaging: efficient threshold or legacy of the past? Eur Urol Focus 9(2):291–297. https://doi.org/10.1016/j.euf.2022.10.002

  9. Schoots IG, Barentsz JO, Bittencourt LK et al (2021) PI-RADS Committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review. AJR Am J Roentgenol 216:3–19. https://doi.org/10.2214/AJR.20.24268

    Article  PubMed  Google Scholar 

  10. Brancato V, Aiello M, Basso L et al (2021) Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions. Sci Rep 11:643. https://doi.org/10.1038/s41598-020-80749-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Grant support: Deutsche Forschungsgemeinschaft DFG (SFB 1340/1-2).

Author information

Authors and Affiliations

  1. Department of Radiology, Charité – Universitätsmedizin Berlin, Berlin, Germany

    Patrick Asbach

  2. Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK

    Anwar R. Padhani

Authors
  1. Patrick Asbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anwar R. Padhani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anwar R. Padhani.

Ethics declarations

Guarantor

The scientific guarantor of this publication is Anwar R Padhani.

Conflict of interest

Patrick Asbach

1. Declares no competing interests relevant to the content of the paper.

2. Institutional research cooperation: Siemens Healthineers, Canon Medical Systems, Bayer AG, Guerbet AG

3. Honoraria/speaker/travel support: European Society of Radiology (ESR), Deutsche Röntgengesellschaft (DRG), Berufsverband der Deutschen Radiologen (BDR), Norddeutsche Röntgengesellschaft, Chinese Society of Radiology (CCR), b.e.imaging

4. Editor: European Journal of Radiology (Elsevier)

5. Employee/consultant/stockholder: none

Prof. Anwar Padhani: no relevant conflict of interest to declare.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

N/A

Ethical approval

N/A

Study subjects or cohorts overlap

N/A

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This comment refers to the article available at https://doi.org/10.1007/s00330-023-09605-0

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asbach, P., Padhani, A.R. Are upgraded DCE-positive PI-RADS 3 lesions truly suspicious for clinically significant prostate cancer?. Eur Radiol 33, 5825–5827 (2023). https://doi.org/10.1007/s00330-023-09711-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-023-09711-z

Search

Navigation